Molecular landscape of the interleukin-40 encoding gene, C17orf99, in patients with acute myeloid leukemia

Acute myeloid leukemia (AML) is a malignant hematological disorder in which aberrant cytokine signaling and inflammation play a role in disease initiation and progression. Interleukin-40 (IL -40) is a novel cytokine encoded by the chromosome 17 open reading frame 99 (C17orf99) gene. This cytokine is involved in mediating inflammation but its biological significance in the pathogenesis of AML has not been investigated. In this casecontrol and observational study, mRNA expression and DNA methylation of the C17orf99 gene were evaluated in the peripheral blood of AML patients. In addition, the polymorphism of two novel intergenic variants of the C17orf99 gene, rs2004339 A/G and rs2310998 G/A, were explored using a real-time polymerase chain reaction assay. The study was conducted on 131 patients with AML and 106 controls and gene expression and DNA methylation were expressed as fold -change (2-Delta Delta Ct). Results revealed that mRNA expression of the C17orf99 gene was down -regulated in AML patients, particularly in females, while up -regulated expression was found in patients with hypoalbuminemia. For DNA methylation, it was up -regulated in AML patients, particularly in females, AML M5 subtype, and CD4-negative and CD14-positive peripheral blood cells. The mutant A allele and the corresponding homozygous AA genotype of rs2004339 was significantly associated with an increased risk of AML. The AA genotype was also associated with significantly up -regulated C17orf99 mRNA expression and DNA methylation of compared to the wild -type GG genotype. In conclusions, C17orf99 mRNA expression showed down -regulated levels in the peripheral blood of AML patients, while DNA methylation was up -regulated. The intergenic variant rs2004339 was associated with susceptibility to AML and had an effect on mRNA expression and DNA methylation.